Blurbs

Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), Avanos Medical (AVNS) and Clearside Biomedical (CLSD)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Halozyme (HALOResearch Report), Avanos Medical (AVNSResearch Report) and Clearside Biomedical (CLSDResearch Report).

Halozyme (HALO)

In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Halozyme, with a price target of $60.00. The company’s shares closed last Tuesday at $43.33.

According to TipRanks.com, Butler has 0 stars on 0-5 stars ranking scale with an average return of -3.7% and a 41.6% success rate. Butler covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Aquestive Therapeutics, and ACADIA Pharmaceuticals.

Currently, the analyst consensus on Halozyme is a Strong Buy with an average price target of $55.40.

See today’s best-performing stocks on TipRanks >>

Avanos Medical (AVNS)

JMP Securities analyst David Turkaly reiterated a Hold rating on Avanos Medical today. The company’s shares closed last Tuesday at $28.84.

According to TipRanks.com, Turkaly is a 4-star analyst with an average return of 6.0% and a 49.8% success rate. Turkaly covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Integra Lifesciences, and OrthoPediatrics.

Avanos Medical has an analyst consensus of Moderate Sell, with a price target consensus of $28.00.

Clearside Biomedical (CLSD)

In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Clearside Biomedical, with a price target of $9.00. The company’s shares closed last Tuesday at $1.61, close to its 52-week low of $1.26.

According to TipRanks.com, Wolleben is a 1-star analyst with an average return of -2.8% and a 42.5% success rate. Wolleben covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Crinetics Pharmaceuticals, and Madrigal Pharmaceuticals.

Currently, the analyst consensus on Clearside Biomedical is a Strong Buy with an average price target of $9.33, a 418.3% upside from current levels. In a report issued on July 26, Wedbush also reiterated a Buy rating on the stock with a $9.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on HALO:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos